Document is current
Any future updates will be listed below
-
Authors
Li, Peng
Zhang, Cuicui
Yang, Sen
Wu, Yingxi
Chen, Haiyang
Ma, Shuxiang
Wu, Yufeng
He, Zhen
Wang, Lili
Liu, Yang
Wang, Qiming
-
Funding
Funding for this research was provided by:
Henan Youth and Middle-aged Health Science and Technology Innovation Leaders Training Project (NO.YXKC2022004)
Henan Health Young and Middle-aged discipline Leader Project (NO.HNSWJW-2022011)
Henan Medical Science and Technology Tackling Program of Provincial-Ministry Joint Major Project (No. SBGJ202401004)
Key Research and Development Projects of Henan Province (NO.251111310100)
Henan Province Health and Youth Subject Leader Training Project ([2020]60)
Leading Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (YXKC2020009)
ZHONGYUAN QIANREN JIHUA (ZYQR201912118)
Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer ([2021]10)
Henan Medical Key Laboratory of Refractory lung cancer ([2020]27)
Henan Refractory Lung Cancer Drug Treatment Engineering Technology Research Center ([2020]4)
Key Research and Development Projects of Henan Province in 2023 − Key technologies of novel precision immunotherapy for refractory malignant tumors (Project No. 231111313300)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 22 September 2025
First Online: 27 October 2025
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the Institute Review Board of the Cancer Hospital Affiliated to Zhengzhou University. Because of the retrospective nature of the study without any intervention, and the data were anonymous, the requirement for patient consent was waived.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
